Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20668099 | 0.86 | GAA (0.68) | HTTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5116180 | 0.82 | PRKCI (0.72) | HTTLMNASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL13431520 | 0.82 | SMN1; SMN2 (0.69) | HTTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5123688 | 0.81 | METAP1 (0.61) | HTTLMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL1901332 | 0.80 | LMNA (0.61) | HTTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8171294 | 0.80 | PRKCI (0.53) | HTTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5121767 | 0.80 | GBA1 (0.60) | HTTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5119781 | 0.80 | PRKCI (0.48) | HTTLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5115192 | 0.79 | PRKCI (0.50) | HTTLMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL13164900 | 0.78 | SMN1; SMN2 (0.73) | HTTLMNASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| WO-2019018359-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY (US) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117968-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | TYMS, DPYD, UMPS | HTT 4107/4885LMNA 3741/4885SMN1; SMN2 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.